We performed a focused review of risk of harms of anti-tumor necrosis factor (TNF) inhibitors in adult rheumatic diseases. Increased risk of serious infections, tuberculosis and other opportunistic infections has been reported across various studies, with etanercept appearing to have modestly better safety profile in terms of tuberculosis and opportunistic infections and infliximab with higher risk of serious infections. Evidence suggests no increase in risk of cancer with anti-TNF biologics, but there is an increased risk of non-melanoma skin cancer. Elderly patients appear to be at increased risk of incident or worsening heart failure with anti-TNF biologic use.
All Keywords
【저자키워드】 Rheumatic diseases, biologics, rheumatoid arthritis, harms, adverse effects, TNF-Inhibitors, TNF biologics,
【저자키워드】 Rheumatic diseases, biologics, rheumatoid arthritis, harms, adverse effects, TNF-Inhibitors, TNF biologics,